Share Price | Vor Biopharma, Inc. Stock Analysis & Recommendation

Q: Is Vor Biopharma, Inc. technically bullish or bearish?

As of 3 September 2025, the technical trend for Vor Biopharma, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by daily moving averages and monthly Bollinger Bands showing bullish signals. However, the weekly MACD and RSI indicate a mildly bearish trend, suggesting some short-term weakness. In terms of performance, the stock has underperformed the S&P 500 over the past week and month, with returns of -16.25% and -25.49% respectively, while it has outperformed on a year-to-date basis with a return of 36.94% compared to the S&P 500's 12.22%.

Q: How big is Vor Biopharma, Inc.?

Market Cap: As of Jun 18, Vor Biopharma, Inc. has a market capitalization of 25.77 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Vor Biopharma, Inc. reported net sales of 0.00 million and a net profit of -118.60 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 96.66 million and total assets of 153.02 million.

Q: What does Vor Biopharma, Inc. do?

Overview: Vor Biopharma, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.Financial Snapshot: Net Profit: -32 Million (Quarterly Results - Mar 2025) Market Cap: USD 25.77 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.84 Return on Equity: -179.50% Price to Book: 0.39Contact Details: Details: No Company Details Available Registrar Address: Not available.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

1.38 M

Shareholding (Mar 2026)

FII

9.10%

Held by 43 FIIs

DII

75.17%

Held by 10 DIIs

Promoter

15.74%

Is Vor Biopharma, Inc. technically bullish or bearish?

20-Sep-2025

As of September 3, 2025, Vor Biopharma, Inc. has a mildly bullish trend influenced by daily moving averages and monthly Bollinger Bands, despite short-term weakness indicated by the weekly MACD and RSI, and while it has underperformed the S&P 500 recently, it has outperformed year-to-date.

View full answer

How big is Vor Biopharma, Inc.?

22-Jun-2025

As of Jun 18, Vor Biopharma, Inc. has a market capitalization of 25.77 million, categorizing it as a Micro Cap company, with net sales of 0.00 million and a net profit of -118.60 million over the latest four quarters.

View full answer

What does Vor Biopharma, Inc. do?

22-Jun-2025

Vor Biopharma, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $32 million and a market cap of $25.77 million. Key financial metrics include a negative P/E ratio, no dividend yield, and a return on equity of -179.50%.

View full answer

Compare Vor Biopharma, Inc. with Similar Stocks

Seer, Inc. (California)TriSalus Life Sciences, Inc.Altimmune, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 601 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

0.08

Return on Equity

16.14%

Price to Book

-0.27

Revenue and Profits:

Net Sales:

(Quarterly Results - Mar 2026)

Net Profit:

-220 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

11.46%

6 Months

13.2%

1 Year

238.55%

2 Years

-39.62%

3 Years

185.8%

4 Years

-84.65%

5 Years

-96.53%

Vor Biopharma, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-257.21%

EBIT to Interest (avg)

-91.69

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.84

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

53.05%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-0.27

EV to EBIT

-1.17

EV to EBITDA

-1.19

EV to Capital Employed

-0.18

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

Negative BV

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bullish

Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Bullish

Mildly Bearish

Dow Theory

No Trend

Mildly Bullish

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2026

Shareholding Compare (%holding)

Majority shareholders

Strategic Entities

Domestic Funds

Held in 21 Schemes (7.48%)

Foreign Institutions

Held by 43 Foreign Institutions (9.1%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Mar 2026 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Mar 2026 is -575.69% vs -5.52% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-35.10",
          "val2": "-32.50",
          "chgp": "-8.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-188.40",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-219.60",
          "val2": "-32.50",
          "chgp": "-575.69%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -495.38% vs 0.85% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-368.80",
          "val2": "-117.70",
          "chgp": "-213.34%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-334.40",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-696.00",
          "val2": "-116.90",
          "chgp": "-495.38%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY

Mar'26

Mar'25

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-35.10

-32.50

-8.00%

Interest

0.00

Exceptional Items

-188.40

0.00

Consolidate Net Profit

-219.60

-32.50

-575.69%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Mar 2026 is 0.00% vs 0.00% in Mar 2025

Consolidated Net Profit

YoY Growth in quarter ended Mar 2026 is -575.69% vs -5.52% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-368.80

-117.70

-213.34%

Interest

0.00

Exceptional Items

-334.40

0.00

Consolidate Net Profit

-696.00

-116.90

-495.38%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -495.38% vs 0.85% in Dec 2024

All Annual Results

Company CV

About Vor Biopharma, Inc.

Vor Biopharma, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available